Expert Review of Anticancer Therapy最新文献

Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients. 释放生存优势：对新发 IV 期乳腺癌患者进行原发肿瘤切除术。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-15 DOI: 10.1080/14737140.2024.2428695

Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang

{"title":"Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients.","authors":"Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang","doi":"10.1080/14737140.2024.2428695","DOIUrl":"10.1080/14737140.2024.2428695","url":null,"abstract":"Background: For patients with de novo stage IV breast cancer (BC), the conditions under which the primary tumor resection (PTR) may offer benefit remain unclear.Methods: The SEER database provides treatment data for patients with de novo stage IV BC. We screened cases of metastatic BC diagnosed from 2010 to 2015, with primary endpoints of overall survival (OS) and cancer-specific survival (CSS).Results: 9252 patients with stage IV de novo BC were enrolled. For OS, median survival time (MST) was 38 months with systematic treatment (ST) compared to 52 months with ST plus PTR (p < 0.001). For CSS, MST was 38 months for ST versus 54 months for ST plus PTR (p < 0.001). The results of the Cox proportional hazards regression analysis regarding PTR, for OS: bone metastasis (aHR 0.664, 95%CI 0.583-0.756, p < 0.001); liver-lung metastasis (aHR 0.528, 95%CI 0.327-0.853, p = 0.009). For CSS: bone metastasis (aHR 0.655, 95%CI 0.571-0.751, p < 0.001); liver-lung metastasis (aHR 0.549, 95%CI 0.336-0.889, p = 0.017). Kaplan-Meier analysis indicated that in patients with bone metastases and liver-lung metastases, PTR could improve survival outcomes.Conclusion: Liver-lung metastases and bone metastases in patients with de novo stage IV BC could enhance both OS and CSS through PTR.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. 曲妥珠单抗-德鲁司坦治疗晚期 HER2 低乳腺癌患者的疗效。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2023-09-12 DOI: 10.1080/14737140.2023.2171993

Ilana Schlam, Sara M Tolaney, Paolo Tarantino

{"title":"The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.","authors":"Ilana Schlam, Sara M Tolaney, Paolo Tarantino","doi":"10.1080/14737140.2023.2171993","DOIUrl":"10.1080/14737140.2023.2171993","url":null,"abstract":"Introduction: Until recently, the available human receptor epidermal growth factor 2 (HER2) targeted agents were ineffective for treating patients with HER2-low expressing breast cancer (defined as immunohistochemical expression of 1+ or 2+ without amplification). The development of novel and potent HER2-directed antibody-drug conjugates, affective at treating HER2-low expressing breast cancers, have changed the way we think about HER2-low expression and expanded the treatment options for many patients with advanced disease.Areas covered: In this review, we summarize the current management of HER2-low breast cancer and commonly encountered challenges such as treatment sequencing and toxicity management.Expert opinion: trastuzumab deruxtecan (T-DXd) is a treatment option for patients with advanced, HER2-low breast cancer, irrespective of the hormone receptor status. The current optimal place in treatment algorithms is after the first line of chemotherapy, both in HR-positive and triple-negative breast cancer; however, other agents are available in this setting and risks and benefits for each should be considered in shared decision making. Up to 10-15% of patients receiving T-DXd develop interstitial lung disease. Patient and clinician education are key to safely implement T-DXd in clinical practice.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1059-1066"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10208624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of trophoblastic tumors : review of evidence, current practice, and future directions. 滋养细胞肿瘤的管理：证据回顾、当前实践和未来方向。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-05-22 DOI: 10.1080/14737140.2023.2215438

Antoine Deleuze, Christophe Massard, Fanny Le Du, Benoit You, Claudia Lefeuvre-Plesse, Pierre-Adrien Bolze, Thibault de la Motte Rouge

{"title":"Management of trophoblastic tumors : review of evidence, current practice, and future directions.","authors":"Antoine Deleuze, Christophe Massard, Fanny Le Du, Benoit You, Claudia Lefeuvre-Plesse, Pierre-Adrien Bolze, Thibault de la Motte Rouge","doi":"10.1080/14737140.2023.2215438","DOIUrl":"10.1080/14737140.2023.2215438","url":null,"abstract":"Introduction: Gestational trophoblastic neoplasia (GTN) is a group of rare tumors characterized by abnormal trophoblastic proliferation following pregnancy including invasive moles, choriocarcinomas, and intermediate trophoblastic tumors (ITT). Although the treatment and follow-up of GTN has been heterogeneous, globally the emergence of expert networks has helped to harmonize its management.Areas covered: We provide an overview of the current knowledge, diagnosis, and management strategies in GTN and discuss innovative therapeutic options under investigation. While chemotherapy has been the historical backbone of GTN treatment, promising drugs such as immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway and anti-angiogenic tyrosine kinase inhibitors are currently being investigated remodeling the therapeutical landscape of trophoblastic tumors.Expert opinion: Chemotherapy regimens for GTN have potential long-term effects on fertility and quality of life, making innovative and less toxic therapeutic approaches necessary. Immune checkpoint inhibitors have shown promise in reversing immune tolerance in GTN and have been evaluated in several trials. However, immunotherapy is associated with rare but life-threatening adverse events and evidence of immune-related infertility in mice, highlighting the need for further research and careful consideration of its use. Innovative biomarkers could help personalize GTN treatments and reduce chemotherapy burden in some patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 7","pages":"699-708"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medullary thyroid carcinoma. 甲状腺髓质癌。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-30 DOI: 10.1080/14737140.2023.2247566

Maria Rosa Pelizzo, Esmeralda Isabella Mazza, Caterina Mian, Isabella Merante Boschin

{"title":"Medullary thyroid carcinoma.","authors":"Maria Rosa Pelizzo, Esmeralda Isabella Mazza, Caterina Mian, Isabella Merante Boschin","doi":"10.1080/14737140.2023.2247566","DOIUrl":"10.1080/14737140.2023.2247566","url":null,"abstract":"Introduction: Medullary thyroid carcinoma (MTC) constitutes approximately 5-10% of all thyroid cancers. Although the tumor forms in the thyroid, it doesn't originate from thyroid cells, but from the C cells or parafollicular cells which produce and release a hormone called calcitonin (CT). Starting from the second half of the 1900s, MTC was progressively studied and defined.Areas covered: This study aims to analyze the history, clinical presentation and biological behavior of MTC, bio-humoral and instrumental diagnosis, molecular profiling, genetic screening, preoperative staging and instrumental procedures, indispensable in expert and dedicated hands, such as high-resolution ultrasonography, CT-scan, MRI and PET/TC. We examine recommended and controversial surgical indications and procedures, prophylactic early surgery and multiple endocrine neoplasia surgery. Also, we discuss pathological anatomy classification and targeted therapies. The role of serum CT is valued both as undisputed and constant preoperative diagnostic marker, obscuring cytology and as early postoperative marker that predicts disease persistence.Expert opinion: With a complete preoperative study, unnecessary or useless, late and extended interventions can be reduced in favor of tailored surgery that also considers quality of life. Finally, great progress has been made in targeted therapy, with favorable impact on survival.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"943-957"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10304062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Quality Control Circle on Patient Outcomes after Hepatocellular Carcinoma Intervention: A Meta-Analysis. 质量控制圈对肝癌干预后患者预后的影响：荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-06-20 DOI: 10.1080/14737140.2023.2219899

Yimin Wang, Yuerong Lai, Li Du, Wenzhen Shen

{"title":"Impact of Quality Control Circle on Patient Outcomes after Hepatocellular Carcinoma Intervention: A Meta-Analysis.","authors":"Yimin Wang, Yuerong Lai, Li Du, Wenzhen Shen","doi":"10.1080/14737140.2023.2219899","DOIUrl":"10.1080/14737140.2023.2219899","url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is one of the most common clinical malignant tumors, and patients undergoing interventional treatment often experience emotional and physical distress in the postoperative period. This meta-analysis aimed to evaluate the effects of quality control circle (QCC) intervention on patient wareness of health education and postoperative complications following hepato-cellular carcinoma (HCC) intervention.Methods: A systematic search was conducted to identify relevant controlled trials on the impact of QCC on patients' knowledge of health education and complications after HCC intervention. The search was conducted using various online databases from the earliest available date to July 2022. Following inclusion and exclusion criteria, data were analyzed using RevMan 5.3 software, and the heterogeneity of the studies was explored.Results: A total of 120 articles were retrieved, and 11 controlled trials were included according to the inclusion and exclusion criteria. Meta-analysis showed that QCC reduced postinterventional fever (OR: 0.41, 95% CI: 0.26, 0.65, P = 0.0002), nausea and vomiting (OR: 0.36, 95% CI: 0.22, 0.58, P < 0.0001), abdominal pain (OR: 0.34, 95% CI: 0.20, 0.56, P < 0.0001), loss of appetite (OR: 0.37, 95% CI: 0.21, 0.68, P = 0.001), improved patient knowledge of health education (OR: 4.84, 95% CI: 3.03, 7.74, P < 0.0001), and increased patient satisfaction with nursing care (OR: 6.63, 95% CI: 4.21, 10.45, P < 0.00001). All differences were statistically significant.Conclusions: QCC after HCC intervention can reduce postoperative fever, nausea and vomiting, abdominal pain, and loss of appetite. It also improves patient knowledge of health education and satisfaction with care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"875-882"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10029714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Triple-negative breast cancers. 三阴性乳腺癌。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-09-14 DOI: 10.1080/14737140.2023.2257393

Steven A Narod, Rebecca Dent

引用次数: 2

Elranatamab: a new promising BispAb in multiple myeloma treatment. Elranatamab：一种在多发性骨髓瘤治疗中有前景的新的BispAb。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-20 DOI: 10.1080/14737140.2023.2236303

Karolina Kociszewska, Martyna Bednarczyk, Sebastian Grosicki

{"title":"Elranatamab: a new promising BispAb in multiple myeloma treatment.","authors":"Karolina Kociszewska, Martyna Bednarczyk, Sebastian Grosicki","doi":"10.1080/14737140.2023.2236303","DOIUrl":"10.1080/14737140.2023.2236303","url":null,"abstract":"Introduction: Multiple myeloma is a B-cell malignancy caused by proliferating plasma cells in the bone marrow microenvironment in collaboration with various cell lineage subsets and growth factors without any perfect regulation and tendency to clonal heterogeneity. Despite remarkable improvement in MM treatment and the overall survival of patients, multiple myeloma remains an incurable disease with the tendency to relapse. Therefore, there is an urgent need for new therapeutic options to provide a stabilized response to treatment with long-term duration.Areas covered: Elranatamab (PF-06863135), is a novel heterodimeric humanized full-length bispecific IgG2 kappa antibody derived from 2 mAbs, the anti-BCMA mAb (PF-06863058) and the anti-CD3 mAb (PF-06863059), not yet licensed in routine use. This binding affinity of elranatamab to BCMA and CD3 has been optimized to potentially prompt more potent T cell-mediated anti-myeloma activity. Subcutaneous (s.c.) administration of elranatamab is superior in comparison to intravenous (i.v.), thus it is associated with lower incidence of adverse events, even in higher doses.Expert opinion: Currently, elranatamab is being investigated in a few clinical studies, and the preliminary results are very encouraging. At the time of writing this review there were no full papers published and all of the data in the literature were based on abstract presentations which carry limitations.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"775-782"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10386140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. BRAF-V600E突变转移性癌症的治疗：新的见解和生物标志物。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-23 DOI: 10.1080/14737140.2023.2236794

Javier Ros, Marta Rodríguez-Castells, Nadia Saoudi, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez

{"title":"Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.","authors":"Javier Ros, Marta Rodríguez-Castells, Nadia Saoudi, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Élez","doi":"10.1080/14737140.2023.2236794","DOIUrl":"10.1080/14737140.2023.2236794","url":null,"abstract":"Introduction: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous lines of treatment. Nonetheless, not all patients respond to encorafenib-based combinations, and some responses are short-lived. Identifying new strategies to boost antitumor activity and improve survival is paramount.Areas covered: The development of targeted therapy for BRAF-V600E mCRC starting with BRAF inhibitors as monotherapy through novel combinations with anti-VEGF or anti-PD1 agents to enhance antitumor activity is reviewed, with a particular focus on the development of predictive and prognostic biomarkers.Expert opinion: There is a crucial need to better understand tumor biology and develop accurate and reliable biomarkers to enhance the antitumor activity of encorafenib-based combinations. The RNF43 mutation is an accurate and reliable predictive biomarker of response, and combinations that target crosstalk between the MAPK pathway, the immune system, and WNT pathways seem promising.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"797-806"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10087782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma. Pembrolizumab用于IIB或IIC黑色素瘤的辅助治疗。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-13 DOI: 10.1080/14737140.2023.2247565

Piotr Rutkowski, Anna M Czarnecka

{"title":"Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.","authors":"Piotr Rutkowski, Anna M Czarnecka","doi":"10.1080/14737140.2023.2247565","DOIUrl":"10.1080/14737140.2023.2247565","url":null,"abstract":"Introduction: Up to 30% of patients with stage IIB and 50% of stage IIC melanoma experience recurrence within 5 years after radical surgery. Adjuvant treatment is expected to improve this prognosis.Areas covered: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that acts against the programmed cell death 1 (PD-1) receptor. Pembrolizumab was first approved in monotherapy for the treatment of unresectable/metastatic melanoma based on the results of the prospective KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 trials. KEYNOTE-716 is the randomized phase III trial of pembrolizumab treatment in resected stage II melanoma. Treatment with pembrolizumab is statistically significant, reducing the risk of recurrence as well as distant metastases risk after primary tumor resection. Pembrolizumab treatment has a 24-month RFS rate of 81.2% (HR 0.64 vs placebo) and a DMFS rate of 88.1%.Expert opinion: 1-year adjuvant pembrolizumab treatment of stage IIB/C melanoma patients significantly reduces recurrence or death risk. The safety profile of adjuvant treatment is not different from previously reported and is manageable. Longer follow-up is required to fully understand the efficacy and safety of adjuvant therapy for stage II melanoma, as the number of patients needed to treat is twice as high as for stage III patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"897-902"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials. 柔性乙状结肠镜筛查对结直肠癌癌症发病率和死亡率的影响：随机对照试验的最新系统回顾和荟萃分析。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-08 DOI: 10.1080/14737140.2023.2245564

Chengren Zhang, Lili Liu, Jingjing Li, Yaochun Lv, Dewang Wu, Shiyun Xu, Cong Cao, Lixia Zhao, Yijun Liu, Xiaolong Ma, Xiongfei Yang, Binbin Du

{"title":"Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials.","authors":"Chengren Zhang, Lili Liu, Jingjing Li, Yaochun Lv, Dewang Wu, Shiyun Xu, Cong Cao, Lixia Zhao, Yijun Liu, Xiaolong Ma, Xiongfei Yang, Binbin Du","doi":"10.1080/14737140.2023.2245564","DOIUrl":"10.1080/14737140.2023.2245564","url":null,"abstract":"Objective: Our objective was to estimate the effect of flexible sigmoidoscopy (FS)-based screening on colorectal cancer (CRC) incidence and mortality by conducting an updated meta-analysis of randomized controlled trials (RCTs).Methods: PubMed, Web of Science, Embase, and Cochrane Library searched for RCTs from database inception to December 2022. The methodological quality of the RCTs was assessed using the Cochrane Collaboration Risk of Bias Tool. RevMan 5.4 was used for this meta-analysis.Results: Four RCTs involving 457, 871 patients were included. This meta-analysis revealed that FS-based screening was associated with a 20% relative risk reduction in CRC incidence [RR = 0.80; 95% CI (0.75, 0.86); P < 0.00001], and a 24% reduction in CRC mortality [RR = 0.76; 95% CI (0.70, 0.82); P < 0.00001]. In addition, this meta-analysis revealed that FS-based screening reduced the incidence[RR = 0.68; 95% CI (0.60, 0.77); P < 0.00001] and mortality[RR = 0.64; 95% CI (0.49, 0.83); P = 0.0007] of distal CRC, but had no significant effect on proximal colon cancer.Conclusion: FS-based screening appeared to be effective in reducing distal CRC incidence and mortality in patients at average risk compared to no intervention, but had no significant effect on proximal colon cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1217-1227"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9951792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0